218 related articles for article (PubMed ID: 26381285)
1. Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.
Bista SR; Haywood A; Hardy J; Norris R; Hennig S
J Clin Pharmacol; 2016 Jun; 56(6):705-13. PubMed ID: 26381285
[TBL] [Abstract][Full Text] [Related]
2. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Oosten AW; Abrantes JA; Jönsson S; de Bruijn P; Kuip EJ; Falcão A; van der Rijt CC; Mathijssen RH
Eur J Clin Pharmacol; 2016 Apr; 72(4):459-67. PubMed ID: 26762381
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
[TBL] [Abstract][Full Text] [Related]
4. Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer.
Kuip EJM; Oldenmenger WH; Thijs-Visser MF; de Bruijn P; Oosten AW; Oomen-de Hoop E; Koolen SLW; Van der Rijt CCD; Mathijssen RHJ
PLoS One; 2018; 13(6):e0198289. PubMed ID: 29883454
[TBL] [Abstract][Full Text] [Related]
5. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F
Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107
[TBL] [Abstract][Full Text] [Related]
6. Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent.
Kress HG; Boss H; Delvin T; Lahu G; Lophaven S; Marx M; Skorjanec S; Wagner T
Eur J Pharm Biopharm; 2010 Jun; 75(2):225-31. PubMed ID: 20152899
[TBL] [Abstract][Full Text] [Related]
7. Transdermal fentanyl in cachectic cancer patients.
Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E
Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446
[TBL] [Abstract][Full Text] [Related]
8. Plasma Concentrations of Fentanyl Achieved With Transdermal Application in Chickens.
Delaski KM; Gehring R; Heffron BT; Negrusz A; Gamble KC
J Avian Med Surg; 2017 Mar; 31(1):6-15. PubMed ID: 28358614
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats.
Carroll GL; Hooper RN; Boothe DM; Hartsfield SM; Randoll LA
Am J Vet Res; 1999 Aug; 60(8):986-91. PubMed ID: 10451210
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous and transdermal fentanyl in alpacas.
Lovasz M; Aarnes TK; Hubbell JAE; Bednarski RM; Lerche P; Lakritz J
J Vet Pharmacol Ther; 2017 Dec; 40(6):663-669. PubMed ID: 28317124
[TBL] [Abstract][Full Text] [Related]
11. Postmortem redistribution of fentanyl in the rabbit blood.
Ceelen L; De Zwart L; Voets M; Hillewaert V; Monbaliu J; Teuns G; Coussement W; Greway T
Am J Forensic Med Pathol; 2012 Jun; 33(2):119-23. PubMed ID: 21389904
[TBL] [Abstract][Full Text] [Related]
12. The Opioid Rotation Ratio From Transdermal Fentanyl to "Strong" Opioids in Patients With Cancer Pain.
Reddy A; Yennurajalingam S; Reddy S; Wu J; Liu D; Dev R; Bruera E
J Pain Symptom Manage; 2016 Jun; 51(6):1040-5. PubMed ID: 26826675
[TBL] [Abstract][Full Text] [Related]
13. Disposition of transdermally administered fentanyl in dogs.
Kyles AE; Papich M; Hardie EM
Am J Vet Res; 1996 May; 57(5):715-9. PubMed ID: 8723888
[TBL] [Abstract][Full Text] [Related]
14. A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Koike K; Terui T; Nagasako T; Horiuchi I; Machino T; Kusakabe T; Hirayama Y; Mihara H; Yamakage M; Kato J; Nishisato T; Ishitani K
Support Care Cancer; 2016 Mar; 24(3):1053-9. PubMed ID: 26248654
[TBL] [Abstract][Full Text] [Related]
15. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
16. Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain.
Nomura M; Inoue K; Matsushita S; Takahari D; Kondoh C; Shitara K; Ura T; Hayashi K; Kojima H; Kamata M; Tatematsu M; Hosoda R; Sawada S; Oka H; Muro K
Clin J Pain; 2013 Jun; 29(6):487-91. PubMed ID: 23328324
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain.
Kokubun H; Ebinuma K; Matoba M; Takayanagi R; Yamada Y; Yago K
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):98-104. PubMed ID: 22764844
[TBL] [Abstract][Full Text] [Related]
18. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Geist MJP; Ziesenitz VC; Bardenheuer HJ; Burhenne J; Skopp G; Mikus G
Sci Rep; 2019 Oct; 9(1):14635. PubMed ID: 31601999
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats.
Lee DD; Papich MG; Hardie EM
Am J Vet Res; 2000 Jun; 61(6):672-7. PubMed ID: 10850844
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl transdermal patch (Durogesic® D-TRANS) for post abdominal laparotomy analgesia: a double blind randomized study.
Hosseini H; Kargar S; Shiryazdi SM; Kargar S; Rezaie F; Neamatzadeh H
Minerva Chir; 2015 Dec; 70(6):401-8. PubMed ID: 25517261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
